Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We descri...

Full description

Saved in:
Bibliographic Details
Published inClinical gastroenterology and hepatology Vol. 21; no. 9; pp. 2407 - 2409.e2
Main Authors Cohen, Nathaniel A., Choi, David, Choden, Tenzin, Cleveland, Noa Krugliak, Cohen, Russell D., Rubin, David T.
Format Journal Article
LanguageEnglish
Published United States Elsevier Inc 01.08.2023
Subjects
Colitis, Ulcerative - drug therapy
Humans
Indans - therapeutic use
Oxadiazoles - therapeutic use
United States
United States
Online AccessGet full text

Cover

More Information
Summary:Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1542-3565
1542-7714
DOI:10.1016/j.cgh.2022.03.035